Why the study?
Patients with Ebstein anomaly of the tricuspid valve frequently require cardiac implantable electronic devices, but the optimal approach for device implantation and management remains to be determined.
Describes the implantation of a dual-chamber leadless pacemaker across a percutaneous tricuspid valve-in-valve prosthesis in a patient with Ebstein anomaly.
Unique challenges complicate CIED placement in Ebstein anomaly; leaves open optimal strategies for prospective study.
Ebstein anomaly of the tricuspid valve (TV) is frequently associated with tachyarrhythmias and bradycardias.1,2 Therefore, patients with Ebstein anomaly may require a cardiac implantable electronic device, such as a pacemaker for bradycardia or an implantable cardioverter-defibrillator (ICD) for tachyarrhythmia management. The optimal approach for cardiac implantable electronic device implantation and management in these patients remains to be determined.3
No takes yet. Share an insight, caveat, or question.
Al‐Ghamdi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: